Table 3.

Treatment-emergent adverse events reported with 10-day decitabine and venetoclax, regardless of attribution.

Treatment-emergent adverse events	Grade 1–2	Grade 3	Grade 4	Grade 5
Infection with ANC <1∙0 ×109/L	0 (0)	77 (46)	2 (1)	5 (3)
Renal Failure	0 (0)	0 (0)	2 (1)	1 (1)
Tumor lysis syndrome	0 (0)	3 (2)	1 (1)	0 (0)
Fever (ANC >1.0 × 109/L)	0 (0)	0 (0)	1 (1)	0 (0)
Hemorrhage, CNS	0 (0)	0 (0)	1 (1)	0 (0)
Febrile neutropenia (ANC <1∙0 ×109/L)	0 (0)	49 (2)	0 (0)	0 (0)
Infection with ANC >1∙0 ×109/L	2 (1)	11 (7)	0 (0)	0 (0)
Hyperbilirubinemia	0 (0)	3 (2)	0 (0)	0 (0)
Diarrhea	8 (5)	2 (1)	0 (0)	0 (0)
Colitis	0 (0)	2 (1)	0 (0)	0 (0)
Mucositis	11 (7)	1 (1)	0 (0)	0 (0)
ALT elevation	1 (1)	1 (1)	0 (0)	0 (0)
Fatigue	1 (1)	1 (1)	0 (0)	0 (0)
Cardiac ischemia	0 (0)	1 (1)	0 (0)	0 (0)
Cough	0 (0)	1 (1)	0 (0)	0 (0)
Esophagitis	0 (0)	1 (1)	0 (0)	0 (0)
Fracture	0 (0)	1 (1)	0 (0)	0 (0)
Muscle weakness	0 (0)	1 (1)	0 (0)	0 (0)
Nausea	10 (6)	0 (0)	0 (0)	0 (0)

Results reported as n (%). Reported are adverse events which occurred in at least 10% of the patients or with at least 1 grade 3/4 event; ANC = absolute neutrophil count. ALT = alanine aminotransferase. There were 6 grade 5 adverse events including 5 infections with grade 3/4 neutropenia which were treatment related, and 1 grade 5 renal failure due to acute tubular necrosis which was unrelated to study regimen.